|
|
| (33 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}} | + | {{gohome}} |
| | + | {{ft|P}} |
| | + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| | + | {{qt|Reviews on covid drug development}} |
| | | | |
| − | current items will be put into the subsections.
| |
| | | | |
| − | *[[reviews on covid drug development]] | + | *'''[[scouting ideas]]''' |
| − | *[[scouting ideas]]
| + | |
| | | | |
| − | *[[Patients on biologicals]] | + | *'''[[PHA Biologicals]]''' |
| − | *[[HMGB1, RAGE]]
| + | |
| − | *[[pre-Interleukin 6]]
| + | |
| − | *[[post-Interleukin 6]]
| + | |
| − | *[[pre-TNFalpha]]
| + | |
| − | *[[post-TNFalpha]]
| + | |
| − | *[[pre-Interleukin 17]]
| + | |
| − | *[[post-Interleukin 17]]
| + | |
| − | *[[pre-Interleukin 1]]
| + | |
| − | *[[post-Interleukin 1]]
| + | |
| − | *[[Inflammasome]] ''colchicine''
| + | |
| − | *[[Methotrexate]]
| + | |
| − | *[[other anti-inflammatory]]
| + | |
| − | *[[NK-kappaB]]
| + | |
| − | *[[STAT 3]]
| + | |
| − | *[[JAK Janus Kinase]]
| + | |
| − | *[[Corticosteroids]]
| + | |
| − | *[[Cytokine absorbers]]
| + | |
| − | *[[Target Complement system]]
| + | |
| − | *[[Target Extracellular traps]]
| + | |
| − | *[[TGF beta]]
| + | |
| − | *[[Anticoagulant in covid19]]
| + | |
| − | *[[Antioxidants]]
| + | |
| − | *[[Stem cells]]
| + | |
| − | *[[MDSC cells]]
| + | |
| − | *[[Interferons]]
| + | |
| | | | |
| | + | *'''[[PHA conventional pharmacology]]''' |
| | | | |
| − | *[[other single compounds]] | + | *'''[[PHA retargeted compounds]]''' |
| − | *[[Retargeted single compounds]]
| + | |
| − | *[[Hydroxychloroquine]]
| + | |
| − | *
| + | |
| − | *[[Target ACE2, Spike protein]]
| + | |
| − | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
| + | |
| − | *[[other antiviral compounds]]
| + | |
| − | *[[AV Remdesivir]]
| + | |
| − | *[[AV Lopinavir]]
| + | |
| − | *[[AV Ivermectin]]
| + | |
| − | *[[AV Arabidol]]
| + | |
| − | *[[AV Favipiravir]]
| + | |
| | | | |
| | + | *'''[[PHA antivirals by mechanism]]''' |
| | | | |
| | + | *'''[[PHA pharmacophore by screened target]]''' |
| | | | |
| − | *[[Vitamin D]] | + | *'''[[PHA ImmunoNutrients]] |
| − | *[[Anorganic nutrients Magnesium]]
| + | |
| − | *[[Anorganic nutrients Selenium]]
| + | |
| − | *[[Anorganic nutrients Zinc]]
| + | |
| − | *[[Nutrition, general]]
| + | |
| − | *[[Exercise, Vibration]]
| + | |
| | | | |
| | + | *'''[[PHA compl altern natural]]''' |
| | | | |
| − | *[[Traditional Chinese Medicine]] | + | *'''[[PHA within indications compounds]]''' |
| − | *[[Natural compounds]]
| + | |
| | | | |
| − | *[[Statins]] | + | *'''[[PHA Serum products]]''' |
| − | *[[Antidiabetic compounds, any]]
| + | |
| − | *[[RSP - On RAS drugs]]
| + | |
| | | | |
| − | *[[Reconvalescent blood products, Passive vaccine]] | + | *'''[[PHA Vaccination]]''' |
| − | *[[Plasmapheresis]]
| + | |
| | + | PHA related options: |
| | | | |
| − | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations
| |
| | *[[Radiation therapy]] | | *[[Radiation therapy]] |
| | *[[Phototherapy]] | | *[[Phototherapy]] |
| − | *[[Active vaccine]] | + | *[[Electric fields]] |
| | + | *[[Treatment other concepts]] |
| | + | |
| | + | |
| | + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| | + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| | + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| | + | Paper is (not yet in PubMed) : |
| | + | |
| | + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| | + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| | + | based on e.g. |
| | | | |
| − | ===-rest-===
| + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| − | {{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}} | + | |
| − | {{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
| + | |
| | | | |
| − | {{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
| + | ======================================================================================= |
| | | | |
| − | {{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
| + | COVID19 is now a CURABLE disease !!! |
| − | {{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
| + | |
| | | | |
| − | ===007=== | + | ======================================================================================= |
| − | {{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}}
| + | |
| − | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
| + | |
| − | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
| + | |
| − | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
| + | |
| − | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
| + | |
| − | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
| + | |
| − | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
| + | |
| − | {{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
| + | |
| − | {{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
| + | |
| − | {{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
| + | |
